Engie Brasil Energia S.A. (EGIE3)
B3 Stock Exchange · Brazil · prices in BRL · close of 27 Oct 2026
Key indicators
| Last close | BRL 28.00 |
|---|---|
| 52-week range | 26.61 – 39.36 |
| Return, 1 month / 3 months | −3.8% / −4.9% |
| Return, 1 year / 3 years | +2.0% / +32.5% |
| Trend | Below its 200-day average |
| RSI (14) | 34 |
| Volatility (1 year) | 28.8% |
| Worst drawdown (1 year) | -26.9% |
| Average daily value traded | 117.02M BRL |
| Dividend yield | 4.0% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Engie Brasil Energia is a Brazilian electricity company based in Florianopolis. It generates power from hydroelectric plants and other renewable sources, and it operates electricity transmission lines. The company sells electricity to distributors, large industrial customers and other users through long-term contracts, and it also trades energy in the Brazilian market. Its operations are spread across several Brazilian states, and it is controlled by the French energy group Engie.
On this site Engie Brasil Energia S.A. appears as a stock on the B3 Stock Exchange (Brazil), code EGIE3, with prices in Brazilian reais (BRL). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Engie Brasil Energia S.A. (EGIE3) trades on the B3 Stock Exchange in Brazil. It last closed at BRL 28.00 on 27 October 2026.
Its price-based Market X-Ray is 51 out of 100 (a fair price profile), ranking 726 of 1,455 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 2.0% and over the last three months it fell 4.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on B3 Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 25 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -10.9% | ||
| From 52-week high | -27.1% | ||
| Momentum | 31 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -4.9% | ||
| 6-month return | -20.0% | ||
| 12-month return, skipping the last month | 6.0% | ||
| Stability (higher is calmer) | 67 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 28.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -26.9% | ||
| Liquidity | 95 · Strong | Trades actively. | |
| Average daily value traded | 117.02M BRL | ||
| Zero-volume days | 0.0% | ||
| Income | 56 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 4.0% | ||
| Years with dividends | 6 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | −10.4% |
|---|---|
| 1 month | −3.8% |
| 3 months | −4.9% |
| 6 months | −20.0% |
| 1 year | +2.0% |
| 3 years | +32.5% |
| 5 years | +87.5% |
Signals
| 50-day / 200-day average | 29.91 / 31.44 |
|---|---|
| Golden / death cross (60 days) | Death, 51 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.02 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 21 Aug 2026 | BRL 0.5442 |
| 5 May 2026 | BRL 0.4845 |
| 18 Dec 2025 | BRL 0.0863 |
| 22 Aug 2025 | BRL 0.8746 |
| 21 Aug 2025 | BRL 1.2340 |
| 7 May 2025 | BRL 0.8697 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on B3 Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.